Immunomedics drug Trodelvy extends survival in breast cancer patients [Yahoo! Finance News]
IMMUNOMEDICS (IMMU)
Last immunomedics earnings: 2/27 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
immunomedics.com/2017/immunomedics-announces-presentations-investor-event-2017-san-antonio-breast-cancer-symposium
Company Research
Source: Yahoo! Finance News
By Manojna MaddipatlaSept 19 Reuters) - Immunomedics Inc's cancer drug Trodelvy, which received accelerated U.S. regulatory approval in April, extended survival time in previously treated patients with an advanced form of breast cancer in a clinical trial, the company said on Saturday.The positive new data could improve Immunomedics' chances of winning full U.S. Food and Drug Administration FDA) approval for Trodelvy, the lead drug of the Morris Plains, New Jersey-based cancer drugmaker. Immunomedics is being acquired by Gilead Sciences Inc for $21 billion under a deal announced on Sept. 14.The FDA granted the drug accelerated approval for its use in metastatic triple-negative breast cancer mTNBC) patients who had previously received at least two prior therapies. Its continued approval is contingent upon the FDA's verification of a clinical benefit in confirmatory trials.Trodelvy reduced the risk of death by 52 percent, with a median overall survival of 12.1 months for patients receiv
Show less
Read more
Impact Snapshot
Event Time:
IMMU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMMU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMMU alerts
High impacting IMMUNOMEDICS news events
Weekly update
A roundup of the hottest topics